Halliburton Company (HAL), Accenture Plc (ACN), Yandex NV (YNDX): Hugh Sloane Loves These Stocks

Hugh Sloane’s Sloane Robinson LLP recently disclosed its Form 13F for the second quarter of 2014. Its equity portfolio is worth more than $159 million, with most of its focus allocated to information technology (34.6%), and energy (30.8%) stocks. Now let’s take a look at some of Sloane’s top stock picks for the quarter.

At the top of Sloane’s list is Halliburton Company (NYSE:HAL), a $57.3 million market cap energy corporation. Even after lowering its holdings at the company by 26% last quarter, the fund still holds 681,400 shares worth about $48.4 million. The position at Halliburton Company (NYSE:HAL) makes up slightly over 30% of Sloane Robinson’s total equity portfolio.

Halliburton Company (NYSE:HAL)

Another major investor in the fund is Donald Chiboucis‘ Columbus Circle Investors, which increased its exposure to Halliburton Company (NYSE:HAL) by 18% from last quarter, and now holds 3,965,168 shares worth around $281.5 million.

New Oriental Education & Tech Grp (NYSE:EDU), a $3.01 billion market cap company, rose from fourth to second position on this list. Sloane Robinson increased its exposure by 83% last quarter, and now holds 1.3 million shares, worth roughly $34.6 million. New Oriental Education & Tech Grp (NYSE:EDU) provides private educational services in China based on the number of program offerings, total student enrollments and geographic presence.

As well, the hedge fund run by billionaire Richard Driehaus, Driehaus Capital, showed similar moves regarding their involvement with New Oriental Education & Tech Grp (NYSE:EDU). After selling 298,588 shares in the company last quarter, the fund now has 774,225 shares with a market value of about $22.7 million.

Coming in third on Sloane’s list is Accenture Plc (NYSE:ACN), a $51.16 billion market cap company engaged in providing management consulting, technology and outsourcing services. The fund boosted its exposure to the company by 5% last quarter, and now holds a total of 327,200 shares of Accenture Plc (NYSE:ACN), worth about $26.5 million. Moreover this position makes up for 16.6% of the fund’s total portfolio.

On the opposite, Winton Capital Management, the hedge fund run by David Harding, went the other direction, lowering its exposure to Accenture Plc (NYSE:ACN) by 45% last quarter. Winton now owns 166,496 shares of the company, with a market value of around $13.2 million.

Next up is 21Vianet Group Inc (NASDAQ:VNET), which moved from the sixth to the fourth position on this list over the last quarter. Sloane Robinson increased its involvement with the $1.84 billion market cap company by 91% last quarter, and now holds 526,000 shares -worth around $15.7 million- of 21Vianet Group Inc (NASDAQ:VNET), a carrier-neutral Internet data center services provider in the People’s Republic of China.

Similar is the case with Israel Englander‘s Millennium Management, which doubled its exposure to the company over the first quarter, disclosing ownership of 925,124 shares, worth about $26.5 million. Moreover, Driehaus Capital, which also picked up a stake in the company over the first quarter, now has a total of 626,696 shares with a market value of nearly $18 million.

Finally, there’s Yandex NV (NASDAQ:YNDX), a $9.41 billion market cap European Internet company and a search provider in Russia. This company fell from second to fifth spot in this list over the last quarter, as the fund lowered its stake in the company by 71%, and now owns 348,382 shares, worth about $12.4 million.

Daniel S. Och is another large shareholder in the company. According to its first quarter filing, Och’s Oz Management invested in Yandex NV (NASDAQ:YNDX) by purchasing 846,000 shares, worth approximately $25.5 million.

Disclosure: Javier Hasse holds no position in any stocks or funds mentioned

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!